Annual Report

Overview

The report describes a landmark Takeda option and license deal for ACI-24.060 and continued progress with Janssen's ReTain Phase 2b anti-Tau program. It also highlights positive interim safety and immunogenicity results from the VacSyn Phase 2 trial in Parkinson's disease. New a-syn and TDP-43 PET imaging agents advanced toward first-in-human clinical development.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services